MedPath

Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study

Conditions
EGFR Mutation Positive Non Small Cell Lung Cancer
Registration Number
NCT01838577
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Brief Summary

The investigators wish to document the distribution of EGFR somatic mutations, and assess the relationship between specific genotype, clinical demographic, therapy, and survival, in a large cohort of EGFR mutant NSCLC.

The investigators also wish to comprehensively investigate the relationship between germline DNA and risk of EGFR mutant NSCLC developing, through a GWAS (Genome-Wide Association Studies) and candidate gene approach, and explore the relationship between germline DNA and clinical outcome, in order to potentially identify germline genetic modifiers of EGFR TKI (Tyrosine Kinase Inhibitor) outcome.

Detailed Description

Objective 1: To identify germline allelic DNA variation associated with somatic EGFR mutation in NSCLC, Objective 2: Correlation between germline allelic variants and survival in EGFR somatic mutant NSCLC.

Objective 3: Study germline allelic DNA variation associated with never /ex light smoking NSCLC.

Objective 4: Catalogue distribution of somatic EGFR mutant genotypes in 1,000 EGFR mutant NSCLC cases and describe their relationship to clinical outcome.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
2000
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
For the second objective, the primary endpoint is Overall survival (OS)5 years from FPI
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Royal Marsden

🇬🇧

Sutton, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath